Cancer Care: Review of Cutaneous Melanoma Quality Performance Indicators

Overview

We welcome your views on the Draft Revised Cutaneous Melanoma Quality Performance Indicator  Engagement Document. 

Please provide comments whether they be on all individual Quality Performance Indicators (QPI) or only those relevant to you.

In particular we are looking for comments on:

• The appropriateness of the QPIs that have been developed.
• The target levels that have been set.
• Feasibility of measuring the QPIs identified in a meaningful and comparative way (i.e. ‘like for like’ comparison).

All comments are welcome, whether they are positive or negative. Comments can be submitted anonymously however we would be grateful if you could provide contact details, should any further clarification on comments be required.

Why your views matter

National Cancer Quality Performance Indicators (QPIs) were developed to drive continuous quality improvement in cancer care across NHSScotland.  The Cutaneous Melanoma QPIs were first published in June 2014.  The QPIs are subject to formal review every 3 years, therefore the second cycle of review has now been undertaken following analysis of Year 6 national comparative data.

In order to ensure success of the National Cancer QPIs in driving quality improvement it is critical that QPIs continue to be clinically relevant and focus on areas which will result in improvements to the quality of patient care. 

Wide clinical and public engagement is crucial to ensure wide inclusiveness of clinical colleagues across NHSScotland.  It is also vital to include the patients and the public as key stakeholders in this consultation to ensure the acceptability of the Quality Performance Indicators. 

What happens next

All responses will be collated for review and decision by the Cutaneous Melanoma Review Group. Those who have participated in the engagement process will receive an overview of the changes made and a copy of the final Cutaneous Melanoma QPI document, ahead of publication in early 2022.